Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy

Table 2 Univariate analysis of factors affecting the overall survival

Characteristics	HR (95%CI)	P value
Pre-NCRT CEA (< 3.55/> 3.55)	0.407 (0.185-0.893)	0.025
Pre-NCRT CA19-9 (< 19.01/> 19.01)	0.437 (0.225-0.849)	0.014
Sex (male/female)	0.478 (0.218-1.049)	0.066
Pathological TNM stage (0-I/II-III)	0.321 (0.141-0.732)	0.007
Pathological vascular invasion (absent/present)	0.556 (0.170-1.821)	0.332
Pathological lymphatic invasion (absent/present)	0.400 (0.141-1.136)	0.085
Pathological perineural invasion (absent/present)	0.534 (0.250-1.141)	0.105
Pathological CRM (negative/positive)	0.826 (0.198-3.449)	0.793
NSTB score (0-1/2)	0.416 (0.217-0.800)	0.009

NCRT: Neoadjuvant chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; TNM: Tumor, node and metastasis; CRM: Circumferential resection margin; NSTB: Novel serum tumor biomarker score.